Catch-up drive kicks off to inoculate infants
RAWALPINDI:
A month-long catch-up vaccination campaign has been launched in Rawalpindi district to immunise children aged 2 to 5 years who missed vaccinations during the previous drive has been launched.
According to medics, the jabs protect against 12 life-threatening diseases, including diphtheria, pneumonia, meningitis, diarrhea, polio, tuberculosis, rubella, typhoid, hepatitis B, pertussis (whooping cough), and tetanus.
The initiative comes in response to an increase in child mortality rates, which have been linked to a gap in immunisation.
Due to a shortage of field staff, many children in the district did not receive the required vaccinations during infancy.
To address this, the health department has now launched this special campaign to ensure these children are protected.
The campaign was inaugurated by Deputy Commissioner Hassan Waqar Cheema, along with Administrator of the District Health Authority and Chief Executive Officer Dr Asif Arbab Khan Niazi.
The launch event was attended by Dr Shumaila, Area Coordinator for WHO in Rawalpindi, Dr Ihsan Ghani, District Health Officer (PS DHA), and other senior health officials.
Speaking at the event, Deputy Commissioner Hassan Waqar Cheema and CEO Dr Asif Arbab Niazi emphasised the importance of coordinated efforts to safeguard public health.
They also highlighted the need for community participation to ensure the campaign's success.
The District Health Authority reaffirmed its commitment to expanding healthcare services and achieving immunization targets through collective efforts.
The campaign is expected to reach thousands of children across the district, with mobile vaccination teams deployed to remote areas to ensure no child is left unvaccinated. Local authorities have urged parents to take advantage of the initiative and ensure their children are protected from preventable diseases. Additionally, health officials have stressed the importance of continuing regular immunization practices to avoid any future gaps in coverage, aiming to safeguard the health and well-being of the next generation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
5 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Business Recorder
3 days ago
- Business Recorder
Qatar urged to upgrade Pakistani surgeons
ISLAMABAD: Pakistan has requested Qatar government to upgrade Pakistani surgeons from category three to category one enabling them to bypass appearing in tests. The request was formerly forwarded by the Federal Minister National Health Services and Regulations Syed Mustafa Kamal's recent visit to Qatar where he met with Qatar' s Health Minister Mansoor bin Ibrahim. The Qatari government assured the minister to seriously consider the request which is a longstanding demand of Pakistani doctors. Meanwhile, Kamal on Tuesday chaired a high level review meeting on polio eradication which was attended by key stakeholders, including the Prime Minister's Focal Person for Polio Eradication, Ayesha Raza Farooq, the Special Secretary Health, Additional Secretary Health, the National Polio Coordinator, as well as representatives from WHO, UNICEF, and provincial health authorities. During the meeting, a comprehensive review of the recent nationwide polio vaccination drive was presented. Over 45 million children were successfully administered the polio vaccine drops. National and provincial coordinators shared detailed updates on the ongoing polio eradication efforts, highlighting progress as well as obstacles. Kamal emphasized that protecting children from polio is a collective national responsibility that requires urgent and sustained efforts from all segments of society. He urged parents to proactively seek out polio workers and ensure the immunization of their children, reminding that safeguarding children's health is a matter of accountability both in this life and the hereafter. The Minister highlighted that while cancer treatment is possible, polio remains an incurable disease, reinforcing the critical need to eliminate the virus through effective vaccination campaigns. He called for a significant policy shift to enhance campaign effectiveness and stressed the importance of unity and societal participation in this national mission. "Only two countries in the world still face the threat of polio," Mustafa Kamal stated, noting ongoing extensive campaigns in Afghanistan, effectively supported by the Taliban government. He expressed his hope for simultaneous polio-free status for both Pakistan and Afghanistan. He concluded by motivating the nation to overcome this challenge, stating, 'If we can defeat India as one nation, we can certainly defeat polio. If Palestine remains polio-free despite war, then what are we waiting for?' The Federal Health Ministry reaffirmed its commitment to intensifying polio eradication efforts to ensure a polio-free Pakistan in the near future. Copyright Business Recorder, 2025
Business Recorder
6 days ago
- Business Recorder
World No Tobacco Day: WHO, GoP join hands to deal with devastating economic & health impacts
ISLAMABAD: The government of Pakistan and the World Health Organization (WHO) have joined hands to jointly collaborate to deal with the devastating economic and health impacts of tobacco, which annually results in the deaths of 164,000 people and financially cause Rs700 billion or $2.5 billion losses to the country. The development came here on the occasion of World No Tobacco Day jointly organised by the WHO and the Ministry of National Health Services. The participants emphasised that all tobacco products on the market, without exception and regardless of the manufacturer, are extremely harmful to health and pose serious risks to people of all ages including children and teenagers. Speaking on the occasion, Additional Secretary Health Laeeq Ahmad said that Pakistan was a proud signatory to the World Health Organization Framework Convention on Tobacco Control, Pakistan remains firmly committed to implementing comprehensive, evidence-based measures to reduce tobacco use. He thanked all partners, including WHO, for their unwavering support. 'Together, let us work towards a tobacco-free Pakistan, a nation where our people can live, work, and thrive in an environment that values health, safety, and well-being,' He said that Pakistan in collaboration with WHO and other partners was committed to work together on urgent and sustainable measures to save lives. Measures include long-term increased taxation, advertising bans, regulation on plan packaging and product design to reduce appeal – especially to vulnerable populations such as children and teenagers, tobacco and nicotine-free public spaces, strict enforcement of tobacco control laws, and medical support for those who want to quit. Research has shown that measures such as tobacco taxation are effective in increasing revenues for the government while also reducing consumption, tobacco-related diseases, and pressure on health systems. Pakistan ratified the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) in 2004, and WHO provides continuous technical support to the Ministry of National Health Services Regulations and Coordination and the Federal Board of Revenue in areas such as tobacco tax policy and track-and-trace implementation. WHO Deputy Representative in Pakistan Ellen Thom said, 'The 164,000 people dead to tobacco every year are not just numbers. They are workers with families. They are sons and daughters. They are also teenagers and children, who are particularly vulnerable and an easy target for the advertisement of the tobacco industry. Let us unmask the appeal. Tobacco is not a candy; it is a killer, and we need to protect our children, our families, and our communities.' Copyright Business Recorder, 2025
